In the BioHarmony Drug Report Database
Xyrem (sodium oxybate) is a small molecule pharmaceutical. Sodium oxybate was first approved as Xyrem on 2002-07-17. It is used to treat cataplexy in the USA. It has been approved in Europe to treat cataplexy and narcolepsy. It is known to target hydroxycarboxylic acid receptor 1. Xyrem’s patents are valid until 2033-03-15 (FDA).
Image (chem structure or protein)